By otakuyassine3@gmail.com 
Schmidt P J Investment Management Inc. decreased its holdings in shares of Stryker Co. (NYSE:SYK – Free Report) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,734 shares of the medical technology company’s stock after selling 279 shares during the period. Stryker accounts for 1.4% of Schmidt P J Investment Management Inc.’s portfolio, making the stock its 21st largest position. Schmidt P J Investment Management Inc.’s holdings in Stryker were worth $7,825,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in SYK. Czech National Bank increased its stake in Stryker by 8.1% during the 3rd quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock valued at $25,231,000 after purchasing an additional 5,235 shares in the last quarter. Dynamic Advisor Solutions LLC grew its holdings in shares of Stryker by 2.3% during the third quarter. Dynamic Advisor Solutions LLC now owns 2,990 shares of the medical technology company’s stock valued at $1,080,000 after buying an additional 67 shares during the last quarter. Atomi Financial Group Inc. raised its holdings in Stryker by 2.3% in the 3rd quarter. Atomi Financial Group Inc. now owns 2,091 shares of the medical technology company’s stock worth $755,000 after acquiring an additional 47 shares during the last quarter. Sugarloaf Wealth Management LLC lifted its position in Stryker by 32.7% in the 3rd quarter. Sugarloaf Wealth Management LLC now owns 446 shares of the medical technology company’s stock valued at $161,000 after acquiring an additional 110 shares in the last quarter. Finally, Reliant Investment Management LLC increased its holdings in shares of Stryker by 0.9% in the 3rd quarter. Reliant Investment Management LLC now owns 15,200 shares of the medical technology company’s stock worth $5,491,000 after purchasing an additional 138 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is currently owned by insiders.
Stryker Stock Performance
SYK opened at $399.01 on Thursday. The stock has a market capitalization of $152.11 billion, a price-to-earnings ratio of 51.42, a PEG ratio of 2.78 and a beta of 0.96. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company has a fifty day moving average of $376.87 and a 200 day moving average of $364.00.
Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business earned $3.46 EPS. As a group, sell-side analysts forecast that Stryker Co. will post 13.5 earnings per share for the current fiscal year.
Stryker Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.84%. Stryker’s payout ratio is currently 43.30%.
Analyst Ratings Changes
A number of brokerages have recently issued reports on SYK. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Truist Financial raised their price target on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Evercore ISI raised their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $419.37.
Check Out Our Latest Stock Report on Stryker
Stryker Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Featured Stories
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Stryker and related companies with MarketBeat.com’s FREE daily email newsletter.